Substantial evidence supports that sodium-glucose cotransporter 2 inhibitors (SGLT-2i) and nonsteroidal mineralocorticoid receptor antagonists (nsMRAs) slow DKD progression when used alongside renin-angiotensin system inhibitors in T2DM patients. This evidence concerns the gene NR3C2 and type 2 diabetes mellitus.